Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

GREY:CLAZF - Post Discussion

Claritas Pharmaceuticals Inc > Patience is a key element of success.... B.Gates
View:
Post by whisky11 on Apr 20, 2021 1:26pm

Patience is a key element of success.... B.Gates

We have to wait until management tell us about progress with the US government to finance the project.
Is there a private business willing to finance phase 1 
When phase 1 starts and how long it will take. Because of urgency, is the project gonna be expedited
Until then $0.05-$0.10
On the bright side we all know R-107 works and is safe.
After successful phase 1we will get another dilemma what is better ,to buy white Ferrari with black interioror to buy black Ferrari with white interior.
Comment by bud13 on Apr 20, 2021 2:21pm
I say both
Comment by Bigginvestor on Apr 20, 2021 3:21pm
lol I'm going for the Aston Martin
Comment by bud13 on Apr 20, 2021 4:29pm
Yap. Y not eh. We waited long enough for it.
Comment by AngelaL on Apr 20, 2021 7:23pm
As far as I understand from the PR's to date, everything is loaded and ready to go into a Phase 1 study. The beauty of their PAH program is that they can leapfrog from a quick Phase 1 study on healthies right to a small Phase 2 in folks with bad PAH. A Phase 2 pilot like that can be done in a few months. Assuming R-107 works in that Phar 2, then they have proof of principle and the stock is ...more  
Comment by Bigginvestor on Apr 20, 2021 8:52pm
wht would sell at ?
Comment by AngelaL on Apr 21, 2021 3:23am
The market valuation of any small biotech with an exciting asset that shows proof of concept in a pilot Phase 2 clinical trial for PAH, testing a novel proprietary technology that has a promising new mechanism of action (as R-107 does), would be in the range of US$400-700 million, possibly stretching to US$800 million if the results are spectacular. Such a prospective market valuation assumes that ...more  
Comment by indaknownewfie on Apr 21, 2021 6:10am
I'm willing to settle for between $15-20 per share. Bearing in mind that the Srpsis market in the US last year was 28 Billion, 1 billion for the Province of Ontario. When you factor in Sepsis occurs in most severe cases of  COVID   start factoring in its application worldwide, the numbers are huge.
Comment by 8CornerPocket on Apr 21, 2021 7:09am
That's around my range too
Comment by 011Peking on Apr 20, 2021 9:05pm
Ya. That is for sure a big dilemma! I'd rather go with a freshly baked Volvo XC90 T8 or someting similar but why not a black ferrari for the weekends! GLTA and let the good times beguine sooner then later!